Two distinct calcitonin (CT) receptor (CTR)-encoding cDNAs (designated GC-2 and GC-10) were cloned and characterized from giant cell tumor of bone (GCT). Both GC-2 and GC-10 differ structurally from the human ovarian cell CTR (o-hCTR) that we cloned previously, but differ from each other only by the presence (GC-10) or absence (GC-2) of a predicted 16-amino acid insert in the putative first intracellular domain. Expression of all three CTR isoforms in COS cells demonstrated that GC-2 has a lower binding affinity for salmon (s) CT (Kd approximately 15 nM) than GC-10 or o-hCTR (Kd approximately 1.5 nM). Maximal stimulatory concentrations of CT resulted in a mean accumulation of cAMP in GC-2 transfected cells that was greater than eight times higher than in cells transfected with GC-10 after normalizing for the number of receptor-expressing cells. The marked difference in maximal cAMP response was also apparent after normalizing for receptor number. GC-2 also demonstrated a more potent ligand-mediated cAMP response compared with GC-10 for both human (h) and sCT (the EC50 values for GC-2 were approximately 0.2 nM for sCT and approximately 2 nM for hCT; EC50 values for GC-10 were approximately 6 nM for sCT and approximately 25 nM for hCT). Reverse transcriptase PCR of GCT RNA indicated that GC-2 transcripts are more abundant than those encoding for GC-10. 
RNA indicated that GC-2 transcripts are more abundant than those encoding for GC-10. In situ hybridization on GCT tissue sections demonstrated CTR mRNA expression in osteoclast-like cells. We localized the human CTR gene to chromosome 7 in band q22. The distinct functional characteristics of GC-2 and GC-10, which differ in structure only in the first intracellular domain, indicate that the first intracellular domain of the CTR plays a previously unidentified role in modulating ligand binding and signal transduction via the G protein/adenylate cyclase system. (J. Clin. Invest. 1995. 95:2680-2691.) Key words: osteoclast * cyclic Introduction Calcitonin (CT)' is a peptide hormone used clinically to treat disorders of bone remodeling, including osteoporosis, Paget's disease of bone, and hypercalcemia of malignancy. The skeletal actions of CT are mediated primarily by direct inhibition of osteoclastic bone resorption (1, 2) . CT also exerts effects on nonskeletal organs. The CT receptor (CTR) has been identified in tissues such as kidney (1) , brain (3, 4) , lung (5) , placenta (6) , ovaries (7) , testes (8) , and spermatozoa (9) . We previously cloned CTR cDNAs from libraries prepared from a porcine kidney cell line (10) , a human ovarian cell line (7) , and a mouse brain ( 11) . Sequence analysis revealed that the CTR is a prototypic member of a distinct family of G proteincoupled receptors that differs in structure from the other families comprising the superfamily of G protein-coupled receptors that are predicted to span cell membranes seven times (7, 10) . This family of proteins includes the receptors for parathyroid hormone/parathyroid hormone-related peptide (12) , secretin (13), vasoactive intestinal peptide (14) , glucagon (15) , glucagon-like peptide-1 (16) , growth hormone releasing hormone (17, 18) , pituitary adenylate cyclase-activating polypeptide ( 19) , corticotrophin-releasing-factor (CRF) (20) , gastric inhibitory polypeptide (21) , and an insect diuretic hormone (22) . CTRs (23, 24) and several related receptors (19, 25) activate both cAMP and accumulation of cytoplasmic Ca2+ second messenger pathways when transfected into receptor-negative cells. The structural mechanisms by which the CTR couples to the G proteins involved in these signaling pathways are yet to be elucidated in view of the unique amino acid sequences contained in the intracellular face of the CTR.
Comparison of the porcine renal CTR (10) to the human ovarian CTR (o-hCTR) (7) revealed the presence of a predicted nonhomologous 16-amino acid peptide insert in the first intracellular domain of the o-hCTR and suggested the existence of transcript splice variants and a complex gene structure, which was recently confirmed by the characterization of the porcine 1 . Abbreviations used in this paper: CRF, corticotropin-releasing-factor; CT, calcitonin; CTR, CT receptor; ECm, 50% maximum effective concentration; GC-2, a CTR isoform from GCT; GC-10, a CTR isoform from GCT; GCT, human giant cell tumor of bone; o-hCTR, a CTR isoform from human ovarian tumor cells ; ORF, open reading frame; RF, restriction fragment; sCT, salmon CT; UTR, untranslated region.
CTR gene (26) . The existence of splice variants is analogous to those of the dopamine D2 (27) , growth hormone releasing hormone (17, 18) , pituitary adenylate cyclase-activating polypeptide ( 19) , CRF (20) , or metabotropic glutamate (28) receptors. Such variants have not been described for most of the G protein-coupled receptors. The cloning of mouse and rat brain CTR cDNAs identified another receptor form that contained a predicted nonhomologous 37-amino acid insert in the second extracellular domain, as well as a form homologous to the original porcine kidney cell receptor (11, 29, 30) . Different binding affinities were noted for these two rodent receptor forms (29, 30) . These observations have confirmed the existence of multiple CTR forms (isoforms) in a single species. Isoforms of the CTR in bone, however, have not been characterized at the molecular level.
Osteoclasts (the bone cell type that expresses the CTR) have been partially purified in small quantities from bone tissues from several species but have not been maintained in culture (31) . Although attempts have been made to isolate osteoclasts from human fetal bone (32) , human fetal tissues are not readily available, and the viability of the isolated cells is poor. To overcome this problem, we chose to characterize potential human skeletal CTR variant(s) in the abundant osteoclast-like cells that are characteristic of human giant cell tumors of bone (GCT), an osteolytic neoplasm (33) . Microscopically, GCTs are characterized by numerous osteoclast-like multinucleated giant cells interspersed among stromal cells. Although these tumors are heterogeneous, there is evidence that a population of stromal cells are the proliferating cells and, therefore, these cells have been considered to constitute the neoplastic population of the tumor (33) (34) (35) (36) . The multinucleated giant cells, on the other hand, are differentiated cells that rarely persist in culture and do not appear in lesions introduced into immunosuppressed mice (35, 37) . These giant cells have been shown to fulfill current criteria for the characterization of in osso osteoclasts (38) , including multinucleation, responsiveness to CT and expression of CTRs, the capacity to form resorption pits in devitalized bone, calcium-sensing, and the presence of tartrateresistant acid phosphatase. These osteoclast-like cells, therefore, provide an abundant source of CTR mRNA (7) for molecular cloning.
We now describe the cloning and characterization of cDNAs from GCT RNA that encode two distinct isoforms of the human CTR. The first form (represented by a clone designated GC-10) differs from the o-hCTR (7) in the 5 '-region in that it lacks a 71-bp segment that contains the first (more 5'-) of two inframe AUG codons found in the o-hCTR, but retains the still more 5'-untranslated nucleotides. GC-10 is virtually identical to the o-hCTR clone in the more 3 domains to assess the presence of variations in these clones that might represent isoforms of the CTR. 10 PCR clones were also sequenced to assess variations that might represent receptor isoforms or mutations and to identify possible single nucleotide substitutions in a particular clone secondary to infidelities resulting from Taq DNA polymerase activity. Sequences were analyzed using the computer programs in Version 7 of the University of Wisconsin Genetics Computer Group (UWGCG) (42) and TopPred II (43).
Construction offull-length CTR cDNAs for expression studies. Fulllength CTR cDNAs incorporating the unique regions found in the GCT-CTR cDNAs were prepared using the cloned GCT PCR products after sequencing 10 clones to confirm the fidelity of the selected clones. The selected clones were digested with EcoRI to isolate a restriction fragment (RF) that included the regions coding for the predicted alternative isoforms recognized among these clones. These EcoRI RFs begin at 5'-untranslated sequence (bp 143 of the o-hCTR) lying upstream of the first in-frame AUG in the o-hCTR and extend to nucleotides that encode the putative second intracellular domain (bp 875 of the o-hCTR). These RFs do not include any sequences from the PCR primers. The isolated GCT-CTR EcoRI-digested RFs were then ligated to the 3 '-sequences of the o-hCTR cDNA contained in the pcDNA I expression vector (Invitrogen) to create sequences corresponding to the entire coding region of the GCT-CTR cDNAs. The regions of the o-hCTR used to create these constructs are identical to the GCT-CTR cDNAs isolated from the phage library with the exception of a single nucleotide substitution (C to T) corresponding to bp 1635 of the o-hCTR sequence. The 3 '-o-hCTR sequences were prepared for subcloning by excision of the corresponding o-hCTR EcoRI fragment and deletion of a major section of the 3'-untranslated region (3'-UTR) 3'-to the NsiI site. In these constructs, therefore, potential 3 '-RNA degradation signals are deleted. We reasoned that deletion of these 3 '-UTR sequences and the resulting smaller plasmid construct might permit higher levels of CTR expression after transfection. An o-hCTR construct with the 3 '-UTR NsiI RF deletion was prepared in the same manner. The orientation and fidelity of ligation products were verified by RF digestion and nucleotide sequencing of the completed constructs. The two different GCT-CTR constructs, designated GC-2 and GC-10, represent native GCT-CTR cDNAs with full-length ORFs determined from the isolated overlapping clones from which they were constructed. They differ from the cloned o-hCTR isoform encoding cDNA as described in Results and in Fig. 2 .
Transfection of COS-M6 cells with CTR cDNAs. "Maxi-prep" plasmid DNA prepared using QIAGEN tips (QIAGEN, Inc., Chatsworth, CA) was used to transfect COS-M6 cells grown in 10-cm plastic dishes (Falcon Plastics, Lincoln Park, NJ) using a DEAE-Dextran/chloroquine procedure (44). Transfection efficiency was determined for each plasmid-CTR isoform construct preparation on a fraction of the transfected cells after plating them on 3-cm plastic dishes and performing in situ 1"I-salmon (s) CT binding followed by fixation, counter staining with methylene blue, and emulsion autoradiography using NTB-2 photoemulsion (Eastman Kodak Co., Rochester, NY) (35) . The 10 -cm culture dishes after splitting and replating. A fraction of the transfected cells used in these assays was also plated on 3-cm plastic dishes to determine the transfection efficiency of each plasmid/CTR cDNA. This protocol permitted the quantitation of CTR-expressing cells in each experiment and the number of receptors expressed per transfected cell using Scatchard analysis.
Analysis of CTR mRNA expression in GCT by in situ hybridization.
Frozen unfixed sections (8) (9) (10) ,m) from five separate GCT tissues were thaw-mounted on gelatin-coated, RNAse-free slides after sectioning on a cryostat at -18'C. Before prehybridization, slides were fixed in 4% paraformaldehyde and treated with 0.2 N HCl, proteinase K, 0.25% acetic anhydride, 2 x SSC followed by dehydration and delipidation.
Templates for in vitro transcription of riboprobes for the human CTRs were prepared by subcloning a 642-bp EcoRI/ApaI RF from the ohCTR cDNA into the vector Bluescript SK II (Stratagene). 35S-labeled sense and antisense riboprobes were then prepared using T3 or T7 polymerase to transcribe the linearized plasmid DNA using the Riboprobe System (Promega Corp.). After hybridization at 550C in 50%
formamide, autoradiography was carried out by dipping the slides in Kodak NTB-2 emulsion, followed by air drying at room temperature and exposure at 40C.
Mapping the human CTR gene by in situ hybridization to metaphase chromosomes coupled with selective PCR amplification using DNA from somatic hybrid cells. The 3.6-kb o-hCTR cDNA in pcDNA I (Invitrogen) was cesium-purified and labeled by nick translation to a spe- (45) . Human metaphase chromosomes were prepared from cultures of peripheral blood lymphocytes from two normal males. In situ hybridization was performed with minor modification of the method previously reported (45) . Hybridized slides were coated with Kodak NTB-2 emulsion and stored in a desiccator at 4°C for 21 d. After development of the autoradiographs, chromosomes were stained in a 50 .g/ml solution of quinacrine mustard dihydrochloride. Locations of silver grains were recorded with reference to an idiogram of Gbanded metaphase chromosomes at the 400 band stage.
To confirm and clarify the CTR gene location results obtained by in situ hybridization, DNA from human-hamster somatic cell hybrids (NA10629 and NA10791 from the NIGMS Human Genetic Mutant Cell Repository, Camden, NJ) that contained selected chromosomes was analyzed by PCR under species-specific conditions. Human-specific CTR primers corresponding to regions homologous to exons identified in the mouse CTR gene ( 11 ) 6 min at 94°C ("hot start"); 45 s at 94°C; 1 min at 55°C; 3 min at 72°C for 30 cycles, then 10 min at 72°C. Taq DNA polymerase, 2.5 U (Promega Corp.), was added after the hot start; the optimized Mg concentration was 2.0 mM. PCR amplification products (10-30% of reactions) were analyzed by agarose gel electrophoresis and Southern blot analysis (39) using a 32P-labeled BglII-PstI RF probe from the o-hCTR. To confirm the specific PCR amplification of the human CTR gene, the positively hybridizing single band amplified from the somatic cell hybrid containing chromosome 7 was cloned into pCR II (Invitrogen) and sequenced.
Results
Cloning and sequence analysis of GCT-derived CTR cDNAs. Five independently isolated clones were obtained after screening 3.6 x 106 plaques from a GCT-cDNA library using plaque hybridization. Insert size ranged from 2.5 to 2.8 kb. Although these clones differed in length at their 3 '-ends, they began at exactly the same 5 '-end corresponding to nucleotide 1051 of the previously reported o-hCTR sequence (7) which encodes part of the putative third transmembrane domain (Fig.  1) . No Reverse transcription-PCR was used to characterize the remaining 5'-sequence of GCT-CTR cDNAs. Specific primers were based on the known sequences from the GCT and o-hCTR clones and were designed to produce products that would include regions of overlap with the existing GCT-CTR cDNAs so that full-length cDNAs could be generated (Fig. 1) The product generated by the Fl/R2 primer set was separated by electrophoresis in low temperature melting agarose and directly sequenced using overlapping inside primers from the regions that encode the predicted first intracellular and second extracellular domains. This method of bulk PCR product sequencing was used to establish the sequence of the major (mathematically most abundant) CTR sequence contained in the isolated band. Rare or less abundant sequence variants (or potential point mutations representing Taq DNA polymerase infidelities) that would comigrate with the major product would not be detected by this method, however. DNA from the same isolated PCR product band was, therefore, also cloned into pCR II. 10 PCR-product clones were isolated and sequenced to characterize less abundant GCT-CTR isoform variants over this region and rule out inconsistent point mutations resulting from Taq DNA polymerase infidelities in clones selected for use in further constructions.
Bulk sequencing of the PCR product revealed that the major GCT-CTR isoform (GC-2 in Fig. 2) does not contain the 48-bp insert found in the o-hCTR corresponding to the region predicted to encode the first intracellular domain. This major product (and by extrapolation, the major transcript) also does not contain the 11 1-bp insert encoding for 37 additional amino acids in the second extracellular domain of the mouse and one rat (CIb) brain CTR isoform (11, 29, 30) . Sequencing of the 10 cloned PCR products revealed that 7 of the 10 clones (represented by clone GC-2) did not contain the 48-bp insert, confirming that this cDNA represents the most abundant transcript derived from GCT mRNA. These seven (GC-2) clones also differed from the o-hCTR in the 5 '-region in that none possessed an insert of 71 bp that included the most 5'-in-frame start site found in the o-hCTR. As previously noted (7), both the 5'-and 3 '-AUG codons found in the o-hCTR clone have an A at the minus 3 position consistent with and sufficient for the minimal Kosak consensus start site (46) . The remaining 3 of the 10 sequenced clones (represented by clone GC-10) also differed from the o-hCTR cDNA in that none contained the 71-bp 5'-insert of the o-hCTR. The GC-2 and GC-10 nucleotide sequences immediately 5'-and 3 '-to the point where the 71-bp insert is located in the o-hCTR cDNA were identical to the o-hCTR sequence with the exception of a single base in the minus 6 position relative to the more 3 '-AUG of the o-hCTR (Fig. 2 B) . The GC-2 and GC-1O clones, therefore, both possess only a single in-frame AUG homologous to the second (3'-) in-frame AUG found in the o-hCTR. The GCT clones represented by GC-10 did, however, possess the other insert of 48 bp found in the o-hCTR (but not in GC-2) in the region encoding the predicted first intracellular domain. This 48-bp insert would be spliced in between a codon of the GC-2 cDNA, resulting in the sequence AGG instead of AGA. Since both of these triplets encode an arginine residue, the predicted amino acid sequence of GC-2 is conserved adjacent to the inserted peptide in the GC-10 and o-hCTR isoforms (Fig. 2 C) . We have confirmed the presence of both GC-2 and GC-10 isoforms in the GCT RNA from each of the two patients tested.
In summary, the isoform encoded by GC-10 is identical to the o-hCTR except that its NH2-terminal sequence lacks 18 predicted amino acids due to the absence of a 5 '-in-frame initiation codon and other inserted nucleotide sequences found in the o-hCTR cDNA. The predicted receptor isoform encoded by GC-2 also lacks these NH2-terminal 18 putative first intracellular domains of the o-hCTR and GC-10 clones. GC-2 is, therefore, homologous to the porcine renal receptor (10) in the putative NH2-terminal region and in the first intracellular domain.
Characterization of "2'I-CT binding to COS-M6 cells transfected with o-hCTR, GC-2, and GC -10 CTR cDNAs. COS-M6 cells were transfected with each of the three distinct human CTR cDNAs representing the three isoforms, as described above. In each of these constructs, part of the 3'-UTR 3'-to the NsiI restriction site was deleted to increase expression. All three constructs are, therefore, identical over the region 3'-to the 48- (Fig. 3) for 1251-sCT competed with unlabeled sCT in COS cells transfected with each isoform-encoding cDNA confirmed the relative lower affinity of the GC-2 isoform (corresponding to its higher KY. by Scatchard analysis) compared with the o-hCTR and GC-10 isoforms (Fig. 3) 
ments) for o-hCTR (not shown). Maximal cAMP responses
for each receptor-encoding cDNA were assayed in parallel experiments. The marked difference in maximal cAMP stimulation between GC-2 and GC-10 was still apparent when the cAMP response was normalized to receptor number (Fig. 5 B) . Cells transfected with the GC-2 receptor and incubated with sCT increased cAMP content to a mean maximum of 23.5 pmol/ receptor x 10-1°(range 17.7-31.7 pmol/receptor X 10-") compared with 8.0 pmol/receptor x 10`0 (range 6.0-9.7 pmol/receptor x 10-10) for the GC-10 receptor. Transfection with the GC-2 or GC-10 cDNAs resulted in the expression of a high number of receptors in the COS cells (2 2.1 X 106 receptors/cell). The level of expression for each receptor was above the threshold value for absolute maximal cAMP stimulation, based on the results observed for the individual CTR receptor isoforms (i.e., at these levels of receptor expression, cAMP accumulation after incubation with the appropriate ligand concentration was maximal [or saturated] and did not increase further as the receptor number per cell increased). These data suggest that the observed difference in ligand-induced increase in cAMP content between GC-2 and GC-10 is the result of the difference in predicted receptor structure involving the first intracellular domain and is not the result of differences in receptor expression. This difference in structure of the CTR must therefore influence the coupling of each receptor isoform to the G protein/adenylate cyclase system in COS cells.
The magnitude of the maximal cAMP response produced by salmon or human CT is approximately the same for any given receptor isoform expressed in COS cells (Fig. 4, B and  C) . The EC50 values for salmon and human CTs, however, reflect the greater potency of sCT (Fig. 4, B and C) . The EC50 value for sCT is 0.2 nM for GC-2 and 6 nM for GC-10. The magnitude of the cAMP response of the GC-2 isoform is increased despite its lower ligand binding affinity (higher Kd) compared with the GC-10 and o-hCTR isoforms and appears to reflect a greater efficiency in coupling of the ligand-occupied GC-2 CTR to cAMP production. The GC-2 isoform is, therefore, capable of signaling through cAMP at concentrations of ligand that do not elicit increases in cAMP levels in COS cells transfected with the GC-10 or o-hCTR isoforms.
Localization of CTR mRNA expression in GCTs by in situ hybridization. To determine which cells in GCTs express CTR mRNA, we analyzed sections from five tumors by in situ hybridization using sense and antisense o-hCTR riboprobes. We observed that expression of CTR mRNA is localized primarily to multinucleated giant cells and smaller multinucleated cells with characteristics of osteoclast-like cells (Fig. 6) Chromosomal mapping of the human calcitonin receptor. In situ hybridization using the complete o-hCTR cDNA to probe spread metaphase chromosomes was performed. A total of 254 silver grains were found from an analysis of 193 metaphase spreads. 20 grains (7.9%) were localized on chromosome 7, and, of these, 8 (3.1% of the total and 40% of the chromosome 7 grains) were confined to 7q22. A schematic representation of chromosome 7 showing the location of the observed silver grains is depicted in Fig. 7 . A secondary peak was observed on chromosome 6 with 5 silver grains located on or directly beside band p12. [Hormone] (nM) To definitively confirm the chromosomal locus of the CTR gene, we attempted to amplify by PCR a portion of the human CTR gene from human-hamster somatic cell hybrids that contained either human chromosome 6 or 7. These reactions used PCR primers from human CTR cDNA sequences (Fig. 8 ) that corresponded to two exons identified in the mouse CTR gene ( 11) . These primers were specific for human DNA samples and produced a single PCR product of 2 kb when total human DNA was used as template (not shown). PCR reactions using these primers did not produce any product when total hamster DNA was used as template (Fig. 8 A) . Ethidium bromide staining of the PCR products amplified from human-hamster somatic cell hybrid DNA after agarose gel electrophoresis (not shown) revealed that a band of the expected size was obtained only from the somatic cell hybrid DNA that contained chromosome 7. DNA from the hybrid that contained chromosome 6 did not yield a visible product. Southern blot analysis of this gel using a 32P-labeled o-hCTR probe (Fig. 8 A) confirmed the identity of the band amplified from human chromosome 7 and did not detect any hybridizing bands amplified from chromosome 6 DNA. We cloned the 2-kb PCR product amplified from the chromosome 7 containing hybrid cell DNA into the vector pCR II and sequenced it from both ends; the predicted human CTR exon sequences downstream of both of the selected PCR primers were found. These exon sequences flanked an intron that included appropriate splice junctions (Fig. 8 B) . These results, taken together with those obtained by chromosomal analysis using in situ hybridization, indicate that the human CTR gene resides on chromosome 7 at band q22.
Discussion
We have characterized cDNAs encoding two skeletal tissue CTR isoforms derived from human GCT of bone and compared these GCT-CTRs with the human ovarian CTR that we cloned previously (7) . The three receptor isoforms differ by the presence or absence of two inserted sequences. The first insert includes an upstream start site that encodes a putative additional 2686 Gorn et al. showing the location of silver grains after in situ hybridization of the human ovarian calcitonin receptor cDNA probe; a peak was seen at 7q22. 26). Localization of the human CTR gene to the -q arm of human chromosome 7, as described here, is consistent with our localization of the mouse CTR gene to the mouse chromosome 6 ( 11); mouse chromosome 6 is homologous to human chromosome 7. Although the porcine CTR has been localized to chromosome 9, the map of the porcine genome is incomplete and we cannot relate this localization to the human and mouse data. Our gene mapping indicates that the human CTR gene also contains introns (Fig. 8 ) and resides at a single location. These observations are consistent with the existence of only one human CTR gene and of alternative splicing of primary transcripts of this gene as the mechanism by which the human CTR isoforms are generated. Several other G proteincoupled receptor genes have been shown to encode multiple isoforms through alternative splicing (17-20, 27, 28) , including a recently described CRF receptor variant that contains a predicted 29-amino acid insert of unknown function in the first intracellular domain (20) . Since the two GCT-CTR isoforms differ only in the first intracellular domain and were expressed in the same COS background, other structural determinants or differences in the expressed cell signal-coupling machinery cannot be evoked to explain the differing functional properties of these isoforms. Although transfection of GC-2 did result in expression of the highest number of receptors, all three CTR isoform-encoding cDNAs yielded very high levels of receptor expression that, in our experience, are above those necessary for maximal (saturation) levels of ligand-induced cAMP accumulation. Furthermore, binding affinity is independent of receptor number and the observed difference in maximal cAMP accumulation is still observed after normalization for transfection efficiency and the number of expressed receptors. Thus, the first intracellular domain sequences of a G protein-coupled receptor must interact directly or indirectly with a G protein, presumably Gs. We cannot exclude the possibility, however, that high levels of expression of either receptor isoform could result in the preferential binding of signaling proteins other than Gs (e.g., Gi or Gq) and thereby could alter the availability of such proteins in a way that potentiates the activation of adenylate cyclase in the GC-2-expressing cells.
Observations on other G protein-coupled receptors with seven transmembrane domains indicate that multiple intracellular domains contribute to functional G protein coupling (47) (48) (49) (50) (51) (52) (53) (54) (55) . The third intracellular domain has been postulated to be the primary site of coupling to Gsa in some receptors (56) , and several residues in this domain have been specifically implicated in G protein coupling (47) (48) (49) (50) 57) . This third intracellular loop shows considerable diversity in sequence among G proteincoupled receptors, however. CTRs possess an unusually short third intracellular loop. Such sequence divergence in the intracellular surfaces of these receptors has hindered the identification of universal G protein-coupling consensus sequences (57, 58) . The second intracellular domain has also been implicated in G protein coupling in a large subgroup of receptors in the G protein-coupled receptor superfamily (47, 54, 55, 59) . Moro et al. (55) proposed that a consensus sequence in the second intracellular domain of these receptors represents a major G protein-coupling site. The distinct family of receptors represented by the CTR does not contain this "consensus" sequence, however.
Mutagenesis experiments by Moro et al. (55) also suggested that the first intracellular domain of some receptors may be involved in coupling to G proteins that activate phospholipase C. Moro et al. (55) observed a 50% reduction in phosphatidylinositol turnover resulting from a mutation introduced into the first intracellular domain of the muscarinic cholinergic receptor. We found that the insert in the first intracellular domain of the GC-10 CTR isoform resulted in a mean decrease in the CT-induced maximal cAMP response of -66% compared with GC-2 (normalized for actual receptor number). The role of specific intracellular domains in coupling to different G proteins is of particular interest since the CTR couples to multiple signaling pathways (23, 24) , possibly dependent upon the stage of the cell cycle (60).
We have not identified the functional significance of the 71-bp 5 '-inserted sequence in the o-hCTR cDNA that encodes for 18 additional amino acids in the NH2-terminal portion of the o-hCTR receptor. The scanning model of Kozak (46, 61) for initiation of mRNA translation predicts that preinitiation complexes rarely or never pass AUG codons with an A in the minus 3 position, such as exists in the o-hCTR 5 '-AUG codon. This analysis, together with the observations reported in this paper that apparent CTR-encoding mRNA splice variants exist in which the 5 '-initiation codon is deleted, suggests that translation of the o-hCTR isoform starts at the first (5'-) AUG. The cloned rat brain CTRs (29, 30) include two potential initiation codons 5 '-to the single AUG found in the cDNAs encoding the porcine renal and GCT-CTR isoforms, suggesting the possibility of additional variants. The middle AUG of the rat brain CTR cDNAs is in a position homologous to that of the 5'-AUG in the o-hCTR. The cloned mouse CTR cDNA (11) , like the o-hCTR, includes one additional 5 '-initiation codon homologous to the middle AUG in the rat clones. Rodent receptors with 5 '-regions homologous to the GCT and porcine renal CTRs that possess only a single start site have not yet been described.
The NH2-terminal 18 amino acids encoded by the 5 '-initiation codon of the o-hCTR does not contain a continuous stretch of hydrophobic amino acids flanked by polar residues and therefore is probably not a membrane-spanning domain or a signal recognition sequence (62). The 22-amino acid sequence following the second methionine (3'-AUG) does contain such a hydrophobic sequence consistent with those found in signal peptides (62). Since the porcine renal cell and GCT-CTRs can be expressed in COS cells, the more 3 '-start codon can encode functional receptors. These facts do not exclude the 5 '-AUG as a possible translation start site for the o-hCTR isoform, however. The additional 18 amino acids encoded by the 5 '-initiation codon, together with the following 22 amino acids, could represent a bipartite leader sequence that might function, for example, in processes involved in subcellular protein targeting or trafficking. Bone and kidney CTRs are targeted to the basolateral surface of the osteoclast and certain renal tubule cells, respectively (63) . Perhaps the truncated leader sequences of the bone GCT and porcine renal CTR isoforms result in the sorting of these CTRs to the basal or basolateral surfaces of the cells in which they are natively expressed. The putative bipartite leader of the o-hCTR may direct this protein to other more or less specific subcellular locations. The sequences responsible for the sorting of certain proteins to the apical or basolateral cell surface of MDCK kidney epithelial cells are in the NH2-terminal domains of these proteins (64, 65) and other receptors that span the membrane seven times are targeted to specific subcellular locations in the development of specialized cells (66) .
The predicted structure of the o-hCTR is most consistent with a protein with seven transmembrane domains and a cleaved signal sequence based on the earlier hydropathy models of von Heijne and Kyte-Doolittle (62). The more recent analysis of von Heijne and others, as applied in the new TopPred II software using the "GES" hydropathy scale and default parameters, is also consistent with a membrane topology model with eight transmembrane domains (43). In this model, the uncleaved hydrophobic central portion of the 22-amino acid signal sequence would double as a stop-transfer membrane anchor and constitute the first transmembrane helical domain as well as a signal recognition sequence. The additional NH2-terminal 18 amino acids encoded by the first (5'-) AUG would then constitute part of an uncleaved cytosolic tail. Such a receptor would possess eight transmembrane domains with the NH2 and COOH termini both residing in the intracellular compartment. Further experiments are required to establish the actual configuration of the CTR proteins in the membrane, the structure of their NH2-terminal domains, and the functional significance of any difference in these domains.
In summary, we have demonstrated the presence of two skeletal CTR isoform-encoding cDNAs from GCT and compared them with a third CTR isoform-encoding cDNA previously isolated from an ovarian carcinoma cell line. Expression of these three receptor isoforms in COS cells and parallel comparisons of ligand binding and ligand-dependent cAMP responses revealed that the first intracellular domain of the CTR is important in the modulation of receptor function and signaling.
